C WorldWide Group Holding A S raised its stake in shares of Dermira, Inc. (NASDAQ:DERM) by 26.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 153,061 shares of the biopharmaceutical company’s stock after purchasing an additional 32,246 shares during the period. C WorldWide Group Holding A S owned 0.37% of Dermira worth $4,133,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. BNP Paribas Arbitrage SA grew its stake in shares of Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 3,975 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 2,203 shares during the last quarter. KCG Holdings Inc. acquired a new stake in shares of Dermira in the first quarter worth $215,000. Legal & General Group Plc grew its stake in shares of Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 963 shares during the last quarter. Finally, Ardsley Advisory Partners acquired a new stake in shares of Dermira in the second quarter worth $291,000. Institutional investors own 98.09% of the company’s stock.
Shares of Dermira, Inc. (NASDAQ DERM) traded down $0.42 during midday trading on Monday, hitting $24.81. The company’s stock had a trading volume of 424,300 shares, compared to its average volume of 410,676. Dermira, Inc. has a 12 month low of $21.35 and a 12 month high of $38.75. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68.
In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of Dermira stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eugene A. Bauer sold 7,500 shares of Dermira stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,400 shares of company stock valued at $822,553. Company insiders own 13.30% of the company’s stock.
Several brokerages have recently issued reports on DERM. Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research note on Thursday. Leerink Swann restated an “outperform” rating and issued a $41.00 price objective (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective (down previously from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Cantor Fitzgerald restated a “buy” rating and issued a $45.00 price objective on shares of Dermira in a research note on Monday, November 6th. Finally, Mizuho reiterated a “buy” rating and set a $43.00 price target (up previously from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Five analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Dermira presently has an average rating of “Hold” and an average price target of $43.33.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/13/c-worldwide-group-holding-a-s-has-4-13-million-holdings-in-dermira-inc-derm.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.